Back

Residual inflammatory risk.

26 August 2022 (08:00 - 19:30)
Organised by:
Congress Presentation Part of: How to deal with residual cardiovascular risk in atherosclerotic disease? New pharmacotherapeutic options Cardiovascular Pharmacotherapy ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Professor Wolfgang Koenig

TUM Universitätsklinikum, German Heart Center, Munich (Germany)

4 More presentations in this session

Presentation thumbnail
Residual risk in dyslipidaemias: from statins to PCSK9 inhibitors and beyond.
Professor E. Stroes (Amsterdam, NL)
Slides Video
Presentation thumbnail
Residual thrombotic risk: from monotherapy to dual pathway inhibition.
Professor B. Rocca (Casamassima, IT)
Slides Video
Presentation thumbnail
Residual diabetic risk: from glucose lowering to cardiovascular protection.
Professor N. Marx (Aachen, DE)
Slides Video
Presentation thumbnail
How to deal with residual cardiovascular risk in atherosclerotic disease? New pharmacotherapeutic options – discussion.
Video

Access the full session

Session thumbnail
How to deal with residual cardiovascular risk in atherosclerotic disease? New pharmacotherapeutic options
Video

The Event

Event poster

ESC Congress 2022

26 August - 29 August 2022
You may be interested in
thumbnail
Congress Session
Inflammation: the next target in atherosclerotic cardiovascular disease care?
thumbnail
Congress Presentation
Redrawing the map: why we must cross boundaries in lipid management
thumbnail
Congress Presentation
CSL112 (apolipoprotein A-I [human]) reduces the elevation in neutrophil-lymphocyte ratio (NLR) induced by acute myocardial infarction

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources